BMY: Message Board for Bristol-Myers Squibb Co. - InvestorVillage


Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
MSG # SUBJECT TYPE AUTHOR SENTIMENT RECS DATE POSTED
10138 ABECMA-related Excerpts from BMY's BCMA CAR-T partner 2seventy bio (TSVT) 2Q2022 Earnings Call GN JBWIN 6 8/11/2022 2:34:27 PM
10137 Re: Drug pricing - Medicare negotiations in healthcare bill GN teflon2000 1 8/11/2022 11:17:43 AM
10136 Building IP: BMY Patent Application re "CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS" GN JBWIN 0 8/11/2022 1:10:42 AM
10135 Building IP: BMY Patent Application re "IMMUNOMODULATORS" GN JBWIN 0 8/11/2022 1:08:56 AM
10134 Building IP: BMY Patent Application re "ANTI-CTLA4 ANTIBODY PRODRUGGABLE (PROBODY) AT A CDR POSITION" GN JBWIN 0 8/11/2022 1:07:31 AM
10133 Building IP: CELG Patent Application re "AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME" GN JBWIN 0 8/11/2022 1:04:56 AM
10132 Building IP: Celgene Quanticel Research Patent Application re "AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME" GN JBWIN 0 8/11/2022 1:03:49 AM
10131 Building IP: Celgene CAR LLC Patent Application re "METHODS OF TREATING A MK2-MEDIATED DISORDER" GN JBWIN 0 8/11/2022 1:02:11 AM
10130 Building IP: JUNO Patent Applcation re "COMBINATION THERAPY OF A CELL-MEDIATED CYTOTOXIC THERAPY AND AN INHIBITOR OF A PROSURVIVAL BCL2 FAMILY PROTEIN" GN JBWIN 0 8/11/2022 1:00:07 AM
10129 Update including Topline Results from Phase 3 KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma GN JBWIN 2 8/10/2022 6:47:29 PM
Previous 2500 Messages Top of Message List Post Message Go to Msg #  




Financial Market Data provided by
.
Loading...